Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be consi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin
Format: Artigo
Idioma:Russo
Publicat: «FIRMA «SILICEA» LLC 2019-11-01
Col·lecció:Российский кардиологический журнал
Matèries:
acute coronary syndrome
prasugrel
p2y12 receptor blocker
Accés en línia:https://russjcardiol.elpub.ru/jour/article/view/3640
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars